Garetosmab: Activin A Antibody and Receptor Biology Overview

Garetosmab is a fully human monoclonal antibody discovered by Regeneron Pharmaceuticals using its VelocImmune platform, in which genetically engineered mice produce antibodies with human variable regions. Its antigen is activin A, and its mode of action is ligand neutralization: by binding activin A, Garetosmab prevents the ligand from assembling an active receptor complex on the cell surface.

• Name: Garetosmab
• Development code: REGN2477
• Class: fully human monoclonal antibody
• Target: activin A (homodimer of inhibin βA subunits)
• Developer: Regeneron Pharmaceuticals

Activins are dimeric members of the TGF-β superfamily built from inhibin β subunits. Activin A is a disulfide-linked homodimer of two βA subunits encoded by the INHBA gene; activin B (βBβB) and activin AB (βAβB) are related dimers. Like other superfamily members, each subunit is synthesized as a precursor with a large N-terminal prodomain that is proteolytically removed to release the mature, cystine-knot growth factor domain.

Activin A shares receptors with several other ligands, including myostatin (GDF-8), GDF-11 and activin B. This overlap is why ligand-selective antibodies such as Garetosmab are useful tools: they allow researchers to block one ligand while leaving related ligands available to signal through the same receptors.

Activin A signals through a hetero-tetrameric complex of serine/threonine kinase receptors:

• Type II receptors: ActRIIA (ACVR2A) and ActRIIB (ACVR2B), which bind the ligand first and are constitutively active kinases
• Type I receptor: primarily ALK4 (ACVR1B), which is recruited into the complex and phosphorylated by the type II receptor in its glycine/serine-rich (GS) domain

The activated type I receptor then phosphorylates the receptor-regulated SMAD2 and SMAD3 proteins. Phospho-SMAD2/3 associate with SMAD4, translocate to the nucleus and regulate transcription of target genes. Non-canonical outputs, including MAPK pathway activation, have also been described.

Activin A has an additional, well-studied interaction with ACVR1 (ALK2). Wild-type ACVR1 forms non-signaling complexes with activin A, whereas the ACVR1 R206H variant responds to activin A by phosphorylating SMAD1/5/8. This receptor-level finding, reported by Regeneron scientists, is a major reason activin A became a research target.

Activin A activity is tightly controlled by extracellular binding proteins, which are frequently measured or used as comparators in Garetosmab research:

• Follistatin and follistatin-like 3 (FSTL3) bind activin A with high affinity and block receptor engagement
• Inhibins (αβ heterodimers), together with the co-receptor betaglycan, antagonize activin signaling at the receptor level
• Cripto and other co-receptors modulate ligand access to type I receptors

Comparing antibody neutralization with follistatin-mediated inhibition helps define how ligand-specific a given readout is.

In vitro, Garetosmab is used to dissect which part of an activin/SMAD signal depends specifically on activin A. Common approaches include:

• SMAD-responsive reporter assays (for example CAGA-luciferase) in cells stimulated with recombinant activin A, with and without antibody
• Phospho-SMAD2/3 immunoblotting or ELISA as a proximal pathway readout
• Binding kinetics by surface plasmon resonance or biolayer interferometry against activin A, activin B, GDF-8 and GDF-11 to establish ligand selectivity
• ACVR1-variant signaling assays measuring SMAD1/5/8 phosphorylation

For the related myostatin antibody, see the trevogrumab research overview.

Garetosmab and trevogrumab are both Regeneron antibodies against TGF-β superfamily ligands that share activin type II receptors. They differ in which ligand they neutralize.

Because both ligands converge on SMAD2/3, combining the two antibodies is a way to study how much ActRII-dependent signaling each ligand contributes.

Garetosmab is an investigational antibody in clinical development by Regeneron, including a Phase 3 program (OPTIMA) and the Phase 2 COURAGE study, in which it was evaluated in combination with trevogrumab and semaglutide. An overview of that study's design is available in the COURAGE study research overview. Registry details are listed at ClinicalTrials.gov (NCT06299098).

Antibody research material is characterized differently from short synthetic peptides. Typical documentation includes size-exclusion chromatography (SEC-HPLC) for monomer content and aggregates, SDS-PAGE or capillary electrophoresis under reducing and non-reducing conditions, intact or subunit mass spectrometry, protein concentration by A280, and endotoxin by LAL. Antibody solutions are generally kept refrigerated or frozen in aliquots, protected from light, and not subjected to repeated freeze–thaw or vigorous agitation. See what a certificate of analysis shows and endotoxin testing.

This overview is provided as a laboratory research reference only.